Update on Drugs and Drug News: March 2001

Update on: Caspofungin Acetate Cancidas 5% Minoxidil Topical Solution Mequinol 2%, Tretinoin 0.1% Solagé Topical Solution Biologically Active Dressing Composite Cultured Skin (CCS) Xtrac Excimer Laser System

Update on Drugs and Drug News: March 2009

Update on Ustekinumab Stelara®, Photopheresis System THERAKOS™ CELLEX™, Calcitriol Vectical™ Ointment, Autologous Collagen Cellular Processing System Isolagen Therapy™.

Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis

Alitretinoin is an oral retinoid which has proven efficacy and safety in the treatment of chronic hand dermatitis through randomized controlled trials.

Update on Drugs & Devices: March-April 2021

The update covers: Cemiplimab-rwlc for IV injection - Libtayo® (Regeneron/Sanofi), HA-based dermal filler - Restylane® Defyne™ (Galderma), Tirbanibulin ointment 1% - Klisyri® (Almirall/Athenex), Anakinra for SC use - Kineret® (Swedish Orphan Biovitrum Sobi™), Immune modulatory vaccines for melanoma - IO102 and IO103 (IO Biotech).

Acitretin Revisited

Acitretin over the last 20 years has proven useful in a number of dermatologic diseases. Evidence of efficacy, side-effect profile, and approach to its use will be reviewed.

Update on Drugs and Drug News: February 2013

February 2013: Update on drugs, approval dates, and comments. Varicella zoster immune globulin (human) injection (Varizig®), Lidocaine 7% + tetracaine 7% cream (Pliaglis®), Isotretinoin capsule (Epuris™) are covered. Devices such as Laser hair therapy iGrow® Hair Growth Platform and LED device for acne Celluma™ are also covered.

Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea

Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea.

Update on Drugs and Drug News: September-October 2016

This update covers Pembrolizumab IV injection (Keytruda®), Hyaluronic acid gel filler (Juvéderm Volbella® XC), Biosimilar of infliximab (Flixabi®), Ceftaroline fosamil for IV infusion (Teflaro®), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® + Lidocaine), Ixekizumab SC injection (Talz®), Adapalene gel 0.1% (Differin® Gel), C1 esterase inhibitor(human) for IV infusion (Berinert®)

HPV Vaccine Update: New Indications and Controversies

Human papillomavirus (HPV) has a predilection for infecting epidermal and mucosal surfaces such as those of the anogenital region. This article discusses presentations of HPV infections, and the role of HPV vaccines.

Update on Drugs and Drug News: December, 1997

Update on: Mupirocin calcium cream 2% Bactroban Cream® Butenafine cream Mentax®Becaplermin gel 0.01% Regranex®Finasteride 1mg tablets Propecia®Minoxidil 5% Rogaine Extra Strength for Men® Dermagraft® Graftskin® (apligraf) UV light as carcinogen

The Impact of Acne on Quality of Life

Optimal acne therapy must take into account not only acne type and severity, but also the impact of this skin disorder on the patient’s quality of life.

Current Concepts in Laser Tattoo Removal

Today, more than 10% of the Western population has at least 1 tattoo, with prevalence of up to one-fourth in the cohort younger than 30 years of age. This article provides an overview of applicable laser systems and therapeutic strategies for optimized tattoo removal.

Soft Tissue Augmentation with Silicone

Adatosil® is a viscous silicone oil which was granted FDA approval in 1994. This designation removes the legal obstacles to usage for soft tissue augmentation. However, physicians are advised to exercise discretion when using this product.

Update on Drugs and Drug News: January 2001

Update on: Lamivudine, Zidovudine and Abacavir Trizivir Loratidine Claritin Amlexanox 5% paste AptheraBotulinum toxin type B Myobloc

New Antibiotics in the Management of Acute Bacterial Skin and Skin Structure Infections

This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.

Update on Drugs & Devices: January – February 2020

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Update on Drugs & Devices: January-February 2021

The latest drug & device update covers: Orladeyo™ (BioCryst Pharmaceuticals), KPL-716 (Kiniksa Pharmaceuticals), Sklice® (Arbor Pharmaceuticals) and Picato® (Leo Pharma)

Aminolevulinic Acid (Levulan®) in Photodynamic Therapy of Actinic Keratoses

The role of photodynamic therapy (PDT) in the treatment of in situ neoplasias and tumors of the skin is steadily increasing. Its principles of photodynamic action include an intratumoral enriched photosensitizer and light activation.

Update on Drugs & Devices: September – October 2018

Updates on Binimetinib + Encorafenib (Mektovi® + Braftovi®), Crisaborole 2% ointment (Eucrisa™), Glycopyrronium tosylate 2.4% cloth (Qbrexza™), Secukinumab for SC injection (Consentyx®), Tecovirimat capsule (Tpoxx), Diacerein 1% ointment (CCP-020), Migalastat capsule (Galafold™), Mogamulizumabkpkc for IV use (Poteligeo®)

Update on Drugs and Drug News: Number 1 2000

Update on: Clobetasol propionate Olux Foam 0.05% Alitretinoin 0.1% gel Panretin Graftskin Apligraf Bexarotene 1% gel Targretin 10% Docosanol Cream Bleomycin ANDA

N-2-butylcyanoacrylate (GluStitch™)

Cyanoacrylates are surgical adhesives that provide another option for wound closure. There are a number of surgical adhesives either currently available or under development. The presently available butylcyanoacrylates and octylcyanoacrylates are reviewed.

Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis

Glycopyrronium tosylate (Qbrexza), a topical anticholinergic therapy, has been shown to be effective in the treatment of primary axillary hyperhidrosis.

The Evolution of Topical Formulations in Psoriasis

Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge.. Read about new topical therapeutic options.

Smoking and Skin Disease

Tobacco smoking is a serious and preventable health hazard that can cause or exacerbate a number of diseases and shorten life expectancy. This article delves into the role of smoking as an etiologic factor in the development of skin disease.

Ingenol Mebutate: An Introduction

The incidence of nonmelanoma skin cancer continues to increase. This article discusses ingenol mebutate, its history, mechanism of action, and recent trial evidence for this emerging therapy are discussed.

Laser Treatment of Leg Veins

The role of lasers and intense pulsed light sources has gained increasing popularity in the management of both cosmetic telangiectasias and medically significant symptomatic varicose vein disease. Combined approaches of sclerotherapy plus laser treatments may produce synergistic results.

Itraconazole (Sporanox®) for Vulvovaginal Candidiasis

Vulvovaginal candidiasis is a common occurrence among women over 25 years of age. The likelihood of developing infection increases with pregnancy, the use of oral contraceptives or antibiotics, or immune disorders. However, in many cases, the etiology of the disorder is unknown.

Skin Treatments Introduced in 2019

A variety of new skin treatments introduced in 2019.

Oral Contraceptives in the Treatment of Acne

Oral contraceptives (OCs) can reduce acne by lowering the production of adrenal and ovarian androgens, by inhibiting 5- alpha-reductase, which in turn, reduces the levels of dihydrotestosterone, and by stimulating sex hormone binding globulin (SHBG), thus reducing the levels of free testosterone.

Nail Psoriasis: Treatment Options

Approximately 50% of patients with psoriasis have nail psoriasis but the life time chance of nail changes must be much higher. Nail changes in psoriasis include pitting, thickening, onycholysis, discoloration, oily spots, splinter hemorrhages and paronychia. Treatment of choice depends on the form the psoriasis takes.

Update on Drugs and Drug News: June, 1997

Update on: Tretinoin gel 0.1% Retin-A Micro® Delavirdine Rescriptor® Nelfinavir Viracept®Calcipotriene ointment Dovonex® Valacyclovir tablet Valtrex®Pulsed Er:Yag laser system Derma 20®Human skin equivalent Apligraf®Podofilox gel 0.5% Condylox®

Therapeutic Advances in Cutaneous T-Cell Lymphoma

A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.

New Developments in Hormonal Therapy for Acne

Oral contraceptives (OCs) are a valuable option for the treatment of women with acne. The use of OCs can be considered across the spectrum of acne disease severity in women. In Canada, three preparations are approved for mild-to-moderate acne, and a fourth is indicated for severe acne.

Update on Sunscreens

Sunscreens have been in use for nearly 70 years. Originally designed to protect against sunburn, enable longer sun exposure and promote tanning, sunscreens are now often promoted as a method for preventing skin cancer and skin aging.

Systemic Retinoids: Chemoprevention of Skin Cancer in Transplant Recipients

Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.

Focus on Diane-35®

Diane-35®, known as Dianette® in some countries, is a combination of cyproterone acetate 2 mg and ethinyl estradiol 0.035 mg. It has recently received regulatory clearance in Canada, but has not yet been approved by the US FDA.

Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa

Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Discussion includes, safety and efficacy in clinical trials.

Update on Drugs and Drug News February 2005

Updates on: Alefacept AMEVIVE® Dapsone Gel 5% Aczone® Nitroglycerin Ointment Cellegesic® Cefdinir Oral Suspension Omnicef® Ultrasonic Skin Permeation Device SonoPrep® Tazarotene Capsules

Novel Flaps for Lip Reconstruction

Reconstruction of the lips requires careful attention to aesthetic and functional goals. We describe our approach to lip repair and present novel methods to maintain symmetry and function, and optimize cosmetic results.

Drug Treatments for Skin Disease Introduced in 2002

An overview and update of skin conditions and treatments introduced in 2002: Quick overview of drug name, indications and regulatory status

POPULAR